2020 American Transplant Congress
Single versus Dual Immunosuppression in Liver Transplantation for Autoimmune Liver Diseases
*Purpose: There is limited evidence on the optimal maintenance immunosuppression after liver transplant (LT) for primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and autoimmune…2019 American Transplant Congress
Clinical Outcomes of Living versus Deceased Donor Liver Transplantation for Primary Sclerosing Cholangitis: A Multicenter 15 Year Experience
*Purpose: MELD-based allocation is known to reduce access to deceased donor liver transplantation (DDLT) for patients with primary sclerosing cholangitis (PSC). Living donor liver transplantation(LDLT)…2018 American Transplant Congress
DCD Utilization in Cholestatic Liver Disease: Distinct Outcomes between PSC and PBC Recipients
Abdominal Transplant Surgery, Oregon Health & Science University, Portland, OR.
Background: Concern for inferior outcomes in patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) have limited utilization of donation after cardiac death…2018 American Transplant Congress
Rituximab Induction to Prevent the Recurrence of PSC after Liver Transplantation-The Lessons Learned from ABO-Incompatible Living Donor Liver Transplantation-
Background: Multiple studies have failed to reveal an effective method for preventing the recurrence of primary sclerosing cholangitis (PSC) after liver transplantation (LTx). A national…2017 American Transplant Congress
Impact of Inflammatory Bowel Disease on Survival and Risk of Retransplantation of Primary Sclerosing Cholangitis Patients Following Liver Transplantation: UNOS Data Analysis.
Background: The impact of inflammatory bowel disease (IBD) on outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC) has been inconclusive. Previous reports suggested…2017 American Transplant Congress
Graft and Patient Survival in Liver Transplantation for Primary Sclerosing Cholangitis with Organs from DCD versus DBD Donors: Analysis of the UNOS Database.
Background: Primary sclerosing cholangitis (PSC) remains a major indication for liver transplantation (LT) worldwide. In an era of limited organ donation pool, assessment of PSC…2017 American Transplant Congress
Course of Inflammatory Bowel Disease Activity in Primary Sclerosing Cholangitis Patients Undergoing Liver Transplantation.
Aim: Primary sclerosing cholangitis (PSC) is associated with inflammatory bowel disease (IBD). We aimed to review disease activity of IBD in patients with PSC undergoing…2017 American Transplant Congress
Plasma Cell Hepatitis in Primary Sclerosing Cholangitis Patients: 15-Year Experience at a Transplant Center.
Background: Plasma cell hepatitis (PCH) is an uncommon liver graft dysfunction which occurs in liver transplant (LT) recipients of different etiologies other than autoimmune hepatitis.…2016 American Transplant Congress
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.
Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI.
Background:The safety and effectiveness of tumor-necrosis-factor-α antagonist (anti-TNF-α) therapy for inflammatory bowel disease (IBD) has not been well-established in patients after liver transplantation (LT). We…2015 American Transplant Congress
Early Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation Has No Negative Impact on Patients outcome'
Liver transplantation (LT) is the only therapeutic option for primary sclerosing cholangitis (PSC), however, recurrence of PSC (rPSC) post-LT occurs at rates ranging from 9-47%.…
American Transplant Congress abstracts